RepliCel Life Sciences Inc. announced that Andrew Schutte has accepted the role of CEO. Mr. Schutte has served as a Director and been a member of both the Science and Operations Committees since 2018. RepliCel's current President and CEO has resigned these roles and will work with the Board on an ongoing basis.

The Company thanks Mr. Buckler for his past service and ongoing commitment to the Company's success. Kevin McElwee, co-founder and Chief Science Officer has agreed to oversee a robust and expanding set of research initiatives. In addition, Ben Austring has been appointed Chief Legal Officer and Operations Manager.

"Ben and Kevin are invaluable assets to the company, having worked regularly with them as a member of the Operations and Science Committee.